Stem Cell Therapy Shows Promise for Heart Disease When Combined with Bypass Surgery

This clinical trial investigated whether adding bone marrow stem cell therapy to standard coronary artery bypass graft (CABG) surgery could improve heart function in patients with chronic coronary artery disease. The study targeted a major clinical challenge: while bypass surgery successfully restores blood flow, it cannot repair heart muscle already damaged by previous heart attacks.

Researchers enrolled 81 participants in a randomized, placebo-controlled trial comparing CABG surgery alone versus CABG plus intramyocardial injection of CD133+ autologous bone marrow stem cells. CD133+ cells are a specific type of stem cell believed to promote tissue regeneration and blood vessel formation. The trial ran from 2009 to 2017, sponsored by Miltenyi Biotec.

Participants received either their own purified CD133+ bone marrow stem cells or placebo injections directly into heart muscle during bypass surgery. The study measured changes in heart function, exercise capacity, and quality of life over time to determine if stem cell therapy provided additional benefits beyond surgery alone.

Unfortunately, the trial was terminated before completion, though specific reasons weren't detailed in available information. This represents a setback for regenerative cardiac medicine, as heart disease remains a leading cause of death and disability worldwide.

Despite the early termination, this research contributes valuable data to the field of cardiac regenerative medicine. The approach of combining stem cell therapy with established surgical procedures represents an important strategy for addressing age-related cardiovascular decline and improving long-term heart health outcomes.